Sign in Subscribe

case report

A collection of 2 issues

Ultra-high TMB POLE-mutated stage II CRC patient develops severe renal toxicity after adjuvant immunotherapy

Skip to content The CRC Digest Ultra-high TMB POLE-mutated stage II CRC patient develops severe renal toxicity after adjuvant immunotherapy A 28-year-old with stage IIB POLE-mutated MSS CRC whose TMB reached 717 mutations/Mb developed severe renal toxicity after off-label adjuvant envafolimab, raising questions about the safety of ICIs in

KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab

Skip to content The CRC Digest KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab A 57-year-old man with KRAS G13D-mutant metastatic rectal cancer and fluoropyrimidine intolerance achieved approximately 16.6 months of disease control with trifluridine/tipiracil plus bevacizumab integrated with liver-directed treatments,